{"id":52883,"date":"2023-01-13T00:02:31","date_gmt":"2023-01-12T23:02:31","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/rule-2-12-announcement-horizon-therapeutics-plc\/"},"modified":"2023-01-13T00:02:31","modified_gmt":"2023-01-12T23:02:31","slug":"rule-2-12-announcement-horizon-therapeutics-plc","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/rule-2-12-announcement-horizon-therapeutics-plc\/","title":{"rendered":"Rule 2.12 Announcement \u2013 Horizon Therapeutics plc"},"content":{"rendered":"
\n

\nNOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION\n<\/p>\n

<\/a><\/p>\n

DUBLIN–(BUSINESS WIRE)–In accordance with Rule 2.12 of the Irish Takeover Panel Act, 1997, Takeover Rules, 2022 (the \u201cIrish Takeover Rules<\/b>\u201d), Horizon confirms that, as of the close of business on January 11, 2023, Horizon\u2019s issued ordinary share capital is comprised of 228,768,464 ordinary shares, nominal value $0.0001 per share (the \u201cOrdinary<\/b> Shares<\/b>\u201d) and 40,000 deferred ordinary shares of \u20ac1.00 each. The Company has 384,366 Ordinary Shares which are held as treasury shares. The Ordinary Shares are admitted to trading on the Nasdaq Global Select Market under the ticker symbol \u201cHZNP\u201d. The International Securities Identification Number for these securities is IE00BQPVQZ61.\n<\/p>\n

\nThe Company confirms that as of January 11, 2023, there were outstanding options to purchase up to 4,803,451 Ordinary Shares and outstanding restricted stock units and performance stock units conferring on their holders vested or unvested rights to convert into, or receive, up to an aggregate of 1,868,932 Ordinary Shares and incremental restricted stock units to be issued of 4,393,081 Ordinary Shares.\n<\/p>\n

\nAbout Horizon<\/b>\n<\/p>\n

\nHorizon Therapeutics plc is focused on the discovery, development and commercialization of medicines that address critical needs for people impacted by rare, autoimmune and severe inflammatory diseases. Our pipeline is purposeful: We apply scientific expertise and courage to bring clinically meaningful therapies to patients. We believe science and compassion must work together to transform lives. For more information on how we go to incredible lengths to impact lives, please visit www.horizontherapeutics.com<\/a>.\n<\/p>\n

\nEnquiries<\/b>\n<\/p>\n

\nHorizon Investor Relations
\n
<\/span>investor-relations@horizontherapeutics.com<\/a>\n<\/p>\n

\nStatement Required by the Irish Takeover Rules<\/b>\n<\/p>\n

\nThe directors of Horizon accept responsibility for the information contained in this document. To the best of the knowledge and belief of the directors of Horizon (who have taken all reasonable care to ensure such is the case), the information contained in this document for which they respectively accept responsibility is in accordance with the facts and does not omit anything likely to affect the import of such information.\n<\/p>\n

\nDealing Disclosure Requirements<\/b>\n<\/p>\n

\nUnder the provisions of Rule 8.3(b) of the Irish Takeover Rules, if any person is, or becomes, \u2018interested\u2019 (directly or indirectly) in 1% or more of any class of \u2018relevant securities\u2019 of Horizon (including by means of an option in respect of, or a derivative referenced to, any such \u2018relevant securities\u2019), that person must publicly disclose all \u2018dealings\u2019 in any \u2018relevant securities\u2019 of Horizon during the \u2018offer period,\u2019 by not later than 3:30 p.m. (E.T.) on the \u2018business day\u2019 following the date of the relevant transaction.\n<\/p>\n

\nIf two or more persons co-operate on the basis of any agreement either express or tacit, either oral or written, to acquire an \u2018interest\u2019 in \u2018relevant securities\u2019 of Horizon, they will be deemed to be a single person for the purpose of Rule 8.3 of the Irish Takeover Rules.\n<\/p>\n

\nA disclosure table, giving details of the companies in whose \u2018relevant securities\u2019 and \u2018dealings\u2019 should be disclosed can be found on the Irish Takeover Panel\u2019s website at www.irishtakeoverpanel.ie<\/a>.\n<\/p>\n

\n\u2018Interests\u2019 in securities arise, in summary, when a person has long economic exposure, whether conditional or absolute, to changes in the price of securities. In particular, a person will be treated as having an \u2018interest\u2019 by virtue of the ownership or control of securities, or by virtue of any option in respect of, or derivative referenced to, securities.\n<\/p>\n

\nTerms in quotation marks are defined in the Irish Takeover Rules, which can be found on the Irish Takeover Panel\u2019s website. If you are in any doubt as to whether or not you are required to disclose a \u2018dealing\u2019 under Rule 8, please consult the Irish Takeover Panel\u2019s website at www.irishtakeoverpanel.ie<\/a> or contact the Irish Takeover Panel at telephone number +353 1 678 9020.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nInvestor Relations
\n
investor-relations@horizontherapeutics.com<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION DUBLIN–(BUSINESS WIRE)–In accordance with Rule 2.12 of the Irish Takeover Panel Act, 1997, Takeover Rules, 2022 (the \u201cIrish Takeover Rules\u201d), Horizon … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-52883","6":"format-standard","7":"category-industry"},"yoast_head":"\nRule 2.12 Announcement \u2013 Horizon Therapeutics plc - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/rule-2-12-announcement-horizon-therapeutics-plc\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Rule 2.12 Announcement \u2013 Horizon Therapeutics plc - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION DUBLIN–(BUSINESS WIRE)–In accordance with Rule 2.12 of the Irish Takeover Panel Act, 1997, Takeover Rules, 2022 (the \u201cIrish Takeover Rules\u201d), Horizon ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/rule-2-12-announcement-horizon-therapeutics-plc\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2023-01-12T23:02:31+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20230112005852\/en\/1460023\/21\/Horizon_Logo_Full-Color_RGB_Registered_Logo.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/rule-2-12-announcement-horizon-therapeutics-plc\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/rule-2-12-announcement-horizon-therapeutics-plc\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Rule 2.12 Announcement \u2013 Horizon Therapeutics plc\",\"datePublished\":\"2023-01-12T23:02:31+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/rule-2-12-announcement-horizon-therapeutics-plc\\\/\"},\"wordCount\":643,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/rule-2-12-announcement-horizon-therapeutics-plc\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230112005852\\\/en\\\/1460023\\\/21\\\/Horizon_Logo_Full-Color_RGB_Registered_Logo.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/rule-2-12-announcement-horizon-therapeutics-plc\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/rule-2-12-announcement-horizon-therapeutics-plc\\\/\",\"name\":\"Rule 2.12 Announcement \u2013 Horizon Therapeutics plc - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/rule-2-12-announcement-horizon-therapeutics-plc\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/rule-2-12-announcement-horizon-therapeutics-plc\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230112005852\\\/en\\\/1460023\\\/21\\\/Horizon_Logo_Full-Color_RGB_Registered_Logo.jpg\",\"datePublished\":\"2023-01-12T23:02:31+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/rule-2-12-announcement-horizon-therapeutics-plc\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/rule-2-12-announcement-horizon-therapeutics-plc\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/rule-2-12-announcement-horizon-therapeutics-plc\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230112005852\\\/en\\\/1460023\\\/21\\\/Horizon_Logo_Full-Color_RGB_Registered_Logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230112005852\\\/en\\\/1460023\\\/21\\\/Horizon_Logo_Full-Color_RGB_Registered_Logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/rule-2-12-announcement-horizon-therapeutics-plc\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Rule 2.12 Announcement \u2013 Horizon Therapeutics plc\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Rule 2.12 Announcement \u2013 Horizon Therapeutics plc - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/rule-2-12-announcement-horizon-therapeutics-plc\/","og_locale":"en_US","og_type":"article","og_title":"Rule 2.12 Announcement \u2013 Horizon Therapeutics plc - Pharma Trend","og_description":"NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION DUBLIN–(BUSINESS WIRE)–In accordance with Rule 2.12 of the Irish Takeover Panel Act, 1997, Takeover Rules, 2022 (the \u201cIrish Takeover Rules\u201d), Horizon ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/rule-2-12-announcement-horizon-therapeutics-plc\/","og_site_name":"Pharma Trend","article_published_time":"2023-01-12T23:02:31+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20230112005852\/en\/1460023\/21\/Horizon_Logo_Full-Color_RGB_Registered_Logo.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/rule-2-12-announcement-horizon-therapeutics-plc\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/rule-2-12-announcement-horizon-therapeutics-plc\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Rule 2.12 Announcement \u2013 Horizon Therapeutics plc","datePublished":"2023-01-12T23:02:31+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/rule-2-12-announcement-horizon-therapeutics-plc\/"},"wordCount":643,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/rule-2-12-announcement-horizon-therapeutics-plc\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230112005852\/en\/1460023\/21\/Horizon_Logo_Full-Color_RGB_Registered_Logo.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/rule-2-12-announcement-horizon-therapeutics-plc\/","url":"https:\/\/pharma-trend.com\/en\/rule-2-12-announcement-horizon-therapeutics-plc\/","name":"Rule 2.12 Announcement \u2013 Horizon Therapeutics plc - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/rule-2-12-announcement-horizon-therapeutics-plc\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/rule-2-12-announcement-horizon-therapeutics-plc\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230112005852\/en\/1460023\/21\/Horizon_Logo_Full-Color_RGB_Registered_Logo.jpg","datePublished":"2023-01-12T23:02:31+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/rule-2-12-announcement-horizon-therapeutics-plc\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/rule-2-12-announcement-horizon-therapeutics-plc\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/rule-2-12-announcement-horizon-therapeutics-plc\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20230112005852\/en\/1460023\/21\/Horizon_Logo_Full-Color_RGB_Registered_Logo.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20230112005852\/en\/1460023\/21\/Horizon_Logo_Full-Color_RGB_Registered_Logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/rule-2-12-announcement-horizon-therapeutics-plc\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Rule 2.12 Announcement \u2013 Horizon Therapeutics plc"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/52883","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=52883"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/52883\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=52883"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=52883"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=52883"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}